[ad_1]
Lab-Evo has closed a new investment round worth €1 million. Founded in 2022 from the idea of Matteo Nobili, the Italian startup specializes in preventive health and well-being, using innovative technologies to deliver accurate laboratory tests anywhere, Led by a single investor: Fincarl Spa, a Milan-based investment firm led by Speranza Carletti.
Growth Strategy
“This new capital increase represents an important recognition of the value of our company and its potential. We are delighted by the trust placed in this project, as we believe that through digitalization we can change the way people access diagnostic and preventive services, making them more accessible, more efficient and personalized,” said Nobili, CEO of Lab-Evo.
A recent survey by the UK Diagnostic Testing Services Patient Association showed that 93% of patients demanded significant improvements Increased investment in diagnostics 91% said new technology was a priority. Many were willing to pay privately to avoid long waits, with 60% saying they were ready to do so and 77% saying they would be willing to get tested at home.
Lab-Evo now aims to “improve and expand the technological platform, facilitate remote access to laboratory analysis and provide personalized well-being solutions”, we read in the startup’s press release. In addition, the new capital injection will be used to support commercial development, with a particular focus on Digitalization of the Healthcare Industry: In fact, the company’s goal is to revolutionize the accessibility of laboratory analysis, offering innovative and safe alternatives to traditional methods.
In addition to enhancing technical and logistical capabilities and purchasing advanced equipment, the investment will also support marketing activities to increase Brand awareness Lab-Evo and consolidates its position as a reliable reference point in the health and well-being market through a range of personalized products and services.
[ad_2]
Source link
